discovery of glp 1 Reflections on the GLP-1 as a satiety hormone: Implications for obesity therapy and future directions GLP-1 Agonists in Cardiovascular Diseases:

Oral administration of allicin to mice lowered ROS production and prevented ROS-induced cardiac hypertrophy by inhibiting pro-inflammatory pathways like mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/glycogen synthase kinase 3 (GSK3) signaling pathways (20)

Injectable treatments involve higher concentrations and deeper tissue penetration

IGF-1 LR3 combats the loss of muscle mass, both by promoting new tissue growth and retarding apoptosis (cell suicide that protects against infection and healthy cells

What is AOD-9604 and Why Fat Cell Targeting Matters AOD-9604 (Advanced Obesity Drug, fragment 9604) is a 16-amino acid peptide fragment derived from the C-terminal region of human growth hormone

Snchez-Alcoholado L, Ordez R, Otero A, Plaza-Andrade I, Laborda-Illanes A, Medina JA, Ramos-Molina B, Gmez-Milln J, Queipo-Ortuo MI (2020) Gut microbiota-mediated inflammation and gut permeability in patients with obesity and colorectal cancer

how could this peptide have any systemic activity